Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

PURPOSE: Guidelines recommend endocrine treatment for estrogen receptor-positive (ER+) breast cancers for up to 10 years. Earlier data suggest that the 70-gene signature (MammaPrint) has potential to select patients that have an excellent survival without chemotherapy and limited or no tamoxifen tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Opdam, M., van der Noort, V., Kleijn, M., Glas, A., Mandjes, I., Kleiterp, S., Hilbers, F. S., Kruger, D. T., Bins, A. D., de Jong, P. C., Schiphorst, P. P. J. B. M., van Dalen, T., Flameling, B., Rietbroek, R. C., Beeker, A., van den Heiligenberg, S. M., Bakker, S. D., Wymenga, A. N. M., Oving, I. M., Bijlsma, R. M., van Diest, P. J., Vermorken, J. B., van Tinteren, H., Linn, S. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239940/
https://www.ncbi.nlm.nih.gov/pubmed/35587322
http://dx.doi.org/10.1007/s10549-022-06618-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239940/
https://www.ncbi.nlm.nih.gov/pubmed/35587322
http://dx.doi.org/10.1007/s10549-022-06618-z

Ejemplares similares